Physician profile
Macy Sun
NPI 1790313047
$7,653.14
in general payments reported to CMS, 2019-2025
57 companies · $3,317 in 2025
The $3,317 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.41 · 2023: $1,641 · 2024: $2,656 · 2025: $3,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,049 · Education: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,048.86 |
| Education | $564.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $705.23 | 2023-2025 | Tagrisso, Enhertu, Calquence |
| Janssen Biotech, INC. | $534.63 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Pfizer INC. | $497.44 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $471.47 | 2023-2025 | Keytruda, Welireg, Lenvima |
| Novartis Pharmaceuticals Corporation | $462.52 | 2023-2025 | |
| Abbvie INC. | $388.45 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.08 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Celgene Corporation | $304.45 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $240.03 | 2022-2025 | Tecentriq, Venclexta, Alecensa |
| Regeneron Healthcare Solutions, INC. | $217.05 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $214.69 | 2023-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $199.94 | 2024-2025 | |
| Lilly USA, LLC | $180.82 | 2023-2025 | Verzenio, Jaypirca |
| Incyte Corporation | $157.79 | 2023-2025 | Jakafi, Monjuvi |
| Seagen INC. | $146.84 | 2023 | Tukysa, Adcetris |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macy Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.